Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Susceptibilities of Non-albicans Candida Species to Echinocandins, Azoles, and Amphotericin B in Tokat, Turkey

Gulgun Yenisehirli 1 , * , Gulsen Ozveren 1 , Aydan Yenisehirli 2 and Yunus Bulut 1
Authors Information
1 Gaziosmanpasa University Faculty of Medicine, Department of Medical Microbiology, Tokat, Turkey
2 Gaziosmanpasa University Faculty of Medicine, Department of Pharmacology, Tokat, Turkey
Article information
  • Jundishapur Journal of Microbiology: June 2018, 11 (6); e59404
  • Published Online: May 30, 2018
  • Article Type: Research Article
  • Received: August 4, 2017
  • Revised: April 30, 2018
  • Accepted: May 2, 2018
  • DOI: 10.5812/jjm.59404

To Cite: Yenisehirli G, Ozveren G, Yenisehirli A, Bulut Y. In Vitro Susceptibilities of Non-albicans Candida Species to Echinocandins, Azoles, and Amphotericin B in Tokat, Turkey, Jundishapur J Microbiol. 2018 ; 11(6):e59404. doi: 10.5812/jjm.59404.

Copyright © 2018, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusions
  • 1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133-63. doi: 10.1128/CMR.00029-06. [PubMed: 17223626]. [PubMed Central: PMC1797637].
  • 2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309-17. doi: 10.1086/421946. [PubMed: 15306996].
  • 3. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28(5):1071-9. doi: 10.1086/514731. [PubMed: 10452637].
  • 4. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55(10):1352-61. doi: 10.1093/cid/cis697. [PubMed: 22893576]. [PubMed Central: PMC4698872].
  • 5. Nguyen MH, Peacock JJ, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100(6):617-23. [PubMed: 8678081].
  • 6. Wingard JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Infect Dis. 1994;19 Suppl 1:S49-53. [PubMed: 7948571].
  • 7. Colombo AL, Guimaraes T, Silva LR, de Almeida Monfardini LP, Cunha AK, Rady P, et al. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol. 2007;28(5):570-6. doi: 10.1086/513615. [PubMed: 17464917].
  • 8. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366-77. doi: 10.1128/JCM.02117-09. [PubMed: 20164282]. [PubMed Central: PMC2849609].
  • 9. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational supplement. CLSI document M27-S4. Wayne: CLSI; 2012.
  • 10. Diekema DJ, Pfaller MA. Utility of antifungal susceptibility testing and clinical correlations. In: Hall GS, editor. Interactions of yeasts, moulds, and antifungal agents: how to detect resistance. New York: Springer Science+Business Media; 2012. p. 131-58.
  • 11. Larone DH, Larone DH. Medically important fungi: a guide to identification. Citeseer; 1987.
  • 12. Park BJ, Arthington-Skaggs BA, Hajjeh RA, Iqbal N, Ciblak MA, Lee-Yang W, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother. 2006;50(4):1287-92. doi: 10.1128/AAC.50.4.1287-1292.2006. [PubMed: 16569842]. [PubMed Central: PMC1426914].
  • 13. Eksi F, Gayyurhan ED, Balci I. In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method. ScientificWorldJournal. 2013;2013:236903. doi: 10.1155/2013/236903. [PubMed: 24250260]. [PubMed Central: PMC3819922].
  • 14. Dagi HT, Findik D, Senkeles C, Arslan U. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey. Ann Clin Microbiol Antimicrob. 2016;15(1):36. doi: 10.1186/s12941-016-0153-1. [PubMed: 27245756]. [PubMed Central: PMC4888423].
  • 15. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007;59(4):767-71. doi: 10.1093/jac/dkl555. [PubMed: 17293369].
  • 16. Panizo MM, Reviakina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol. 2009;47(2):137-43. doi: 10.1080/13693780802144339. [PubMed: 18651308].
  • 17. Rezazadeh E, Sabokbar A, Moazeni M, Rezai MS, Badali H. Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections. Jundishapur J Microbiol. 2016;9(7). e34151. doi: 10.5812/jjm.34151. [PubMed: 27679703]. [PubMed Central: PMC5035436].
  • 18. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50(6):2009-15. doi: 10.1128/AAC.00163-06. [PubMed: 16723559]. [PubMed Central: PMC1479149].
  • 19. Santos ER, Dal Forno CF, Hernandez MG, Kubica TF, Venturini TP, Chassot F, et al. Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. Rev Inst Med Trop Sao Paulo. 2014;56(6):477-82. [PubMed: 25351540]. [PubMed Central: PMC4296866].
  • 20. Bustamante B, Martins MA, Bonfietti LX, Szeszs MW, Jacobs J, Garcia C, et al. Species distribution and antifungal susceptibility profile of Candida isolates from bloodstream infections in Lima, Peru. J Med Microbiol. 2014;63(Pt 6):855-60. doi: 10.1099/jmm.0.071167-0. [PubMed: 24667770].
  • 21. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006;42(7):938-44. doi: 10.1086/500939. [PubMed: 16511756].
  • 22. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study I. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48(4):1270-5. doi: 10.1128/JCM.02363-09. [PubMed: 20129963]. [PubMed Central: PMC2849617].
  • 23. Badiee P, Alborzi A, Shakiba E, Farshad S, Japoni A. Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents. East Mediterr Health J. 2011;17(5):425-30. [PubMed: 21796956].
  • 24. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Muhlethaler K, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect. 2014;20(7):698-705. doi: 10.1111/1469-0691.12440. [PubMed: 24188136].
  • 25. Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M, Ecmm-Fimua Study Group . Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61(Pt 3):389-93. doi: 10.1099/jmm.0.037895-0. [PubMed: 22096131].
  • 26. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51(8):2571-81. doi: 10.1128/JCM.00308-13. [PubMed: 23720791]. [PubMed Central: PMC3719648].
  • 27. Haddadi P, Zareifar S, Badiee P, Alborzi A, Mokhtari M, Zomorodian K, et al. Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol. 2014;7(9). e11858. doi: 10.5812/jjm.11858. [PubMed: 25485060]. [PubMed Central: PMC4255375].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments